Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population
Cancer Medicine · 2025
DOI: 10.1002/cam4.70790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tatsuro Murano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biomarkers, Tumor, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Background
Gastric cancer (GC) has a high prevalence in Asian countries, and there is an unmet need for non‐invasive and efficient GC screening methods. This study evaluated the diagnostic efficacy of GASTROClear, a panel of blood serum miRNAs for the detection of GC, in a Japanese population.
Methods
We conducted a pilot cohort study, comprising 103 patients with GC and 122 healthy controls. Serum samples were prospectively collected from study participants at two Japanese hospitals using a predefined blood‐processing protocol. The diagnostic performance of GASTROClear was analyzed using a receiver operating characteristic curve and cutoff. By applying a logistic regression algorithm, we evaluated the diagnostic efficacy of novel combinations of GC diagnostic biomarker panels, consisting of GASTROClear and alternative serum markers (anti‐ Helicobacter pylori [Hp] antibody and pepsinogen).
Results
Most patients had Stage I (58%) GC and were asymptomatic (59%). The area under the curve (AUC) value for the detection of GC using GASTROClear was 0.80, with 70.9% sensitivity and 75.2% specificity. GASTROClear performed equally well within the subgroups based on age, sex, symptoms, Hp status, and tumor characteristics. We improved the diagnostic performance of GASTROClear by combining it with an anti‐Hp antibody and pepsinogen. This yielded an AUC value of 0.88, with the highest specificity (86.9%) at a fixed sensitivity (70.9%).
Conclusions
GASTROClear demonstrated competent diagnostic efficacy for GC in the detection of GC in our Japanese cohort, even in the early stages of cancer and asymptomatic cases. Its combination with existing serum markers may contribute to efficient risk stratification to detect GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
- MiRXES Lab Pte Ltd., Singapore.
- Department of Gastroenterology, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
- Department of Pathology, National Cancer Center Hospital East, Chiba, Japan.
- Department of Genetic Medicine and Services, National Cancer Center Hospital East, Chiba, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Murano, T., Chung, K. Y., Tang, Y. C., Kano, Y., Takeuchi, K., Sakamoto, N., Kuwata, T., Gao, Y., Cheong, J. K., Cheng, H., Zhou, L., & Yano, T. (2025). Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population. Cancer Medicine. https://doi.org/10.1002/cam4.70790
Vancouver
Murano T, Chung KY, Tang YC, Kano Y, Takeuchi K, Sakamoto N, et al. Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population. Cancer Medicine. 2025. doi:10.1002/cam4.70790
BibTeX
@article{Murano2025,
author = {Murano, Tatsuro and Chung, Ka Yan and Tang, Yew Chung and Kano, Yuki and Takeuchi, Ken and Sakamoto, Naoya and Kuwata, Takeshi and Gao, Yuan and Cheong, Jit Kong and Cheng, He and Zhou, Lihan and Yano, Tomonori},
title = {Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70790}
}
EUVIMED